Welcome to our dedicated page for Mammoth Energy Svcs SEC filings (Ticker: TUSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the storm-restoration receivables or hydraulic fracturing margins inside Mammoth Energy Services’ dense SEC disclosures can feel like hunting for a drill bit in a sand mine. Each 10-K spans hundreds of pages and every 8-K on new grid contracts lands without warning, leaving professionals wondering, “Where can I quickly grasp what matters?”
Stock Titan’s platform solves this in seconds. Our AI-powered summaries translate complex accounting for Mammoth Energy Services quarterly earnings report 10-Q filing, flag environmental contingencies in plain language, and surface Mammoth Energy Services insider trading Form 4 transactions the moment they post. Need the latest Mammoth Energy Services 8-K material events explained or a concise view of Mammoth Energy Services proxy statement executive compensation? We capture every form—10-K, 10-Q, 8-K, DEF 14A, S-8—then layer real-time alerts, ratio calculators and expert context so you can monitor segment swings, capital-spending plans, and grid-rebuild revenue without poring over footnotes.
Analysts use our coverage to:
- Track Mammoth Energy Services Form 4 insider transactions real-time and spot executive buying patterns
- Compare pressure-pumping fleet utilisation across quarters with AI-generated charts
- Review litigation updates tied to Puerto Rico grid work via curated 8-K briefs
Crinetics Pharmaceuticals, Inc. (CRNX) filed a Form 8-K under Item 7.01 (Regulation FD). The filing discloses that the company issued a press release announcing eight scientific abstracts from its endocrine and rare-disease pipeline that will be presented at the Endocrine Society’s Annual Meeting (ENDO 2025) in San Francisco, July 12-15, 2025.
The abstracts will cover development candidates atumelnant (ACTH antagonist), paltusotine (oral SST2 agonist), and the TSHR antagonist CRN12755. The company also reiterates plans for the potential commercial launch of PALSONIFY (commercial name for paltusotine) if regulatory approval is obtained.
No new clinical data, financial figures, or transaction details are provided in the 8-K; the disclosure is limited to notification of the upcoming presentations. All forward-looking statements are qualified by customary risk factors, including clinical, regulatory, and geopolitical uncertainties.
Mammoth Energy Services, Inc. (NASDAQ: TUSK) filed an 8-K announcing the sale of all hydraulic fracturing equipment held by subsidiaries Stingray Pressure Pumping LLC and Mammoth Equipment Leasing LLC to MGB Manufacturing, LLC for $15.0 million in cash. The divested assets belong to the Company’s Well Completion segment and the transaction closed concurrently with the signing of the Equipment Purchase Agreement on 16 June 2025. Piper Sandler & Co. acted as exclusive advisor.
Because the carrying value of goodwill related to the hydraulic fracturing business now exceeds fair value, Mammoth expects to record a non-cash impairment charge of $7.7-$9.2 million in Q2 2025.
The Company also referenced its previously disclosed T&D Transaction—the April 2025 divestiture of three transmission & distribution subsidiaries—and filed unaudited pro forma condensed consolidated financial statements (Exhibit 99.1) reflecting both divestitures.
Key implications for investors:
- Immediate liquidity boost of $15 million.
- Streamlining of portfolio away from capital-intensive pressure pumping operations.
- Expected goodwill impairment nearly offsets transaction proceeds, pressuring near-term earnings but non-cash in nature.
- Future revenue and EBITDA from hydraulic fracturing will cease unless replaced by new lines or acquisitions.
FAQ
What is the current stock price of Mammoth Energy Svcs (TUSK)?
What is the market cap of Mammoth Energy Svcs (TUSK)?
What does Mammoth Energy Services Inc do?
Which core services are offered by the company?
How does Mammoth differentiate itself in a competitive market?
What role does well completion play in their business model?
In which markets does Mammoth primarily operate?
How does Mammoth ensure operational transparency and reliability?
What are the key industry trends impacting the company?
Is Mammoth involved in infrastructural services beyond oilfield operations?
